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Background: The Elecsys® HIV combi PT assay was developed to allow earlier detection of HIV infection
with increased sensitivity and speciﬁcity.
Objectives: To validate the assay for screening and reliable early detection of HIV-1 infection in Asia.
Study design: Samples tested reﬂected those routinely screened in Asia and comprised: HIV-1 antigen
lysate (25 samples) and antibody (20 samples) dilutions; seven HIV-1 seroconversion panels (46 sam-
ples); 39 patient samples from early infection; 183 known-positive sera; HIV-1 p24 antigen sensitivity
panel (seven samples); >500 routine clinical samples per center. The Elecsys® HIV combi PT assay was
compared with fourth- (ADVIA Centaur® HIV combo, ARCHITECT® HIV combo, Elecsys® HIV combi) and
third-generation (VIRONOSTIKA® HIV Uni-Form II Plus O, Zhuhai Livzon Anti-HIV EIA, Serodia® Particle
Agglutination) assays commonly used in the region.
Results: Overall, the Elecsys® HIV combi PT showed superior or similar sensitivity to the comparators for
detecting all subtypes. The assay correctly identiﬁed all positive samples, including those taken soon after
infection, and detected seroconversion at a similar or shorter time interval than the comparators. The
analytical sensitivity of Elecsys® HIV combi PT for HIV-1 p24 antigen was 0.90 IU/mL, which was lower
than reported previously. The
the other fourth-generation as
Conclusions: These robust data
assay and its suitability for scr
© 201
Abbreviations: Ab, antibody; Ag, antigen; AHI, acute HIV infection; HBs, hep-
titis B surface; HIV, human immunodeﬁciency virus; IR, initially reactive; NA, not
vailable; N/A, not applicable; NAT, nucleic acid test; NIBSC, National Institute for
iological Standards and Control; PCR, polymerase chain reaction; RNA, ribonucleic
cid; s/co, signal to cut-off ratio; WHO, World Health Organization.
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Open access under CC BY-NC-ND lassay showed good speciﬁcity (99.86%) that was superior or equivalent to
says tested.
demonstrate the good subtype inclusivity of the Elecsys® HIV combi PT
eening and reliable early detection of HIV infection in Asia.
3 The Authors. Published by Elsevier B.V.
1. Background
The prevalence of HIV in Asia ranges from <0.1 to 1.3%, with
estimated prevalences of <0.1%, 0.1%, and 0.5% in Korea, China,
and Malaysia, respectively.1 An estimated ﬁve million people in
Asia are currently living with HIV, including 380,000 who were
newly infected in 20072 and ∼140,000 children.3 Given the trend
for recent increases inHIV infections in Asia (for example, the num-
ber of people living with HIV in China rose from ∼470,000 in 2001
to ∼780,000 in 20114), adequate surveillance and prevention of
transmission are an essential part of managing the epidemic.
The transmission risk for HIV is highest during the acute or very
early stages of infection5–7 with transmission rates in the ﬁrst 6
Open access under CC BY-NC-ND license.months estimated to be 5.5–26 times higher than later in the dis-
ease course.7–9 Acute HIV infection (AHI; detection of HIV RNA or
p24 antigen in blood before antibodies have formed)10 is a critical
driver and accounts for 10–50% of all new infections.
icense.
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Identifying acutely infected individuals has been limitedby test-
ng methods requiring substantial investments in infrastructure
nd time.10 It relies on detecting viral nucleic acid or HIV-speciﬁc
ntigens (p24) in the patient’s blood before antibodies are present.
he sensitivity of third-generation HIV enzyme immunoassays is
imited by the fact that they only detect antibodies to HIV-1/-2
hich restricts their ability to identify earlyHIV infection. European
egislation requires that commercially available assays now need
o detect both antigen and antibodies, with a sensitivity for detec-
ion of p24 antigen of <2 IU/mL.11 Hence, several fourth-generation
ombination immunoassays were developed.12–14 However, false-
egative results havebeenattributed to an inability ofHIV serologic
ssays, including fourth-generation combination assays, to detect
hediverse rangeofHIV strains. A recentpaperby Lyet al.15 demon-
trated that the sensitivity of currently available commercial assays
aried according to HIV genotype and cautioned that this could
ompromise diagnosis of early infection. A limitation of their study
as the use of cell culture isolates to assess sensitivity and the
uthors highlighted the need to establish test performance using
ative serum samples from infected individuals.
This study evaluated the updated Elecsys® HIV combi PT assay
sing samples that included those collected from routine practice
t several sites within Asia. The Elecsys® HIV combi PT assay
as developed as an update to the Elecsys® HIV combi assay and
ncorporates the following improvements: a pre-treatment step to
ncrease the sensitivity for HIV-1 p24 antigen and speciﬁcity; a set
f anti-p24 antibodies to provide high sensitivity for p24 antigen
nd allowdetection of early infection, late-phase infection, and p24
ntigenderived fromHIV-1groupOandHIV-2; anda set of antigens
o provide high sensitivity for anti-HIV-1 and anti-HIV-2 antibodies
nd increase detection of antibodies against all subtypes.16
. Objectives
To evaluate the Elecsys® HIV combi PT assay (Roche Diagnostics
mbH, Penzberg, Germany) as a routine screening assay in Asia, an
mportant population for HIV testing with a unique set of HIV sub-
ypes. The study aimed to provide robust data on the Elecsys® HIV
ombi PT assay by assessing it in routine laboratory settings using
large number of samples reﬂecting those screened in the Asian
egion. In addition to determining assay subtype inclusivity, the
bjectives of this multicenter study included validating the capa-
ility of the Elecsys® HIV combi PT assay for the early detection of
IV infection and comparison with other assays commonly used in
sia for HIV testing.
. Study design
.1. Centers and assays compared
Six centers in Asia were involved in the study (Table 1).
ach center tested the Elecsys® HIV combi PT assay17 using
he cobas® e 411 or MODULAR® ANALYTICS E170 immunoassay
nalyzer, and at least one of the following comparators in rou-
ine use at their center, as shown in Table 1: ADVIA Centaur®
IV Ag/Ab combo (Siemens Healthcare Diagnostics Inc., Deerﬁeld,
SA),18 ARCHITECT® HIVAg/Ab combo (Abbott Laboratories,Wies-
aden, Germany),19 Elecsys® HIV combi (Roche Diagnostics GmbH,
enzberg, Germany),20 VIRONOSTIKA® HIV Uni-Form II Plus O
bioMérieux, Shanghai, China),21 Serodia® HIV1/2 Particle Agglu-
ination (Fujirebio, Tokyo, Japan),22 and Zhuhai Livzon Anti-HIV
IA (Zhuhai Livzon Diagnostics Inc., Zhuhai, China).23 The Elecsys®
IV combi PT, Elecsys® HIV combi, ADVIA Centaur® HIV combo,
nd ARCHITECT® HIV combo assays are fourth-generation assays,
hereas the VIRONOSTIKA® HIV Uni-Form II Plus O, Serodia® Par-irology 58 (2014) 221–226
ticle Agglutination, and Zhuhai Livzon Anti-HIV EIA assays are
third-generation tests.
3.2. Samples, methods, and analyses
A total of 4785 different samples were available for testing in
this study. Details of the individual samples tested by each center
are given in Table 1.
To determine the sensitivity for detecting different HIV-1 sub-
types, 25 virus lysate samples representing HIV-1 subtypes A, B,
C, CRF01 AE, and F were prepared by Roche Diagnostics GmbH
by diluting virus lysate supernatants with HIV-negative serum
(dilution factors of 1:3000 to 1:128,000). Samples were stored as
frozen aliquots at −20 ◦C. Detection of subtype antigen relies on
the ability of the assay to detect p24 antigen and therefore the
lysate dilutions were only assessed using the fourth-generation
assays (Elecsys® HIV combi PT, ADVIA Centaur® HIV combo,
and ARCHITECT® HIV combo assays). Twenty antibody dilutions
were similarly prepared from highly anti-HIV-1-positive sam-
ples from patients infected with HIV-1 subtypes A, B, C, D, and
CRF01 AE (dilution factors 1:150 to 1:850,000) and provided by
Roche Diagnostics GmbH. These samples were used to assess the
ability of the fourth- and third-generation assays to detect anti-
bodies to the various subtypes. Samples were stored as frozen
aliquots at −20 ◦C. In addition, 183 samples from HIV-positive
patients were provided and tested by two of the centers (30
samples from China and 153 from Malaysia; Table 1) to inves-
tigate the sensitivity of the assays for detecting known-positive
samples.
Seven different commercially available HIV-1 seroconversion
panels representing a maximum of 46 samples were used. Pan-
els were purchased from SeraCare Life Sciences Inc. (Milford, USA;
panels PRB958 and PRB930) and North American Biologicals Inc.
(Boca Raton, USA; panels 4099, 25165, 9003, 1436, and 0759)
and comprised samples taken from patients before and after they
tested positive for HIV infection and throughout the immune
response. The panels were evaluated to assess how early each
assay could detect infection and data calculated using the Paul
Ehrlich Institute model, as described previously.16 Sensitivity for
early detection was also assessed using 39 single samples taken
from patients 9 to >800 days after HIV infection. These samples
were stored at −20 ◦C as frozen aliquots and tested after thawing
once.
A deﬁned HIV-1 p24 antigen sensitivity panel was used to
measure the lower limit of detection of the fourth-generation
assays. TheNIBSC/WHOHIV-1 p24Antigen International Reference
Standard was purchased from NIBSC (London, UK) and dilutions of
0.0, 0.32, 0.62, 1.13, 2.34, 4.54, and 8.92 IU/mL were tested. Ana-
lytical sensitivity was determined using Graphpad Prism 5.0 to
generate a linear regression.
The speciﬁcity of the screening assays was determined using
samples collected at each center as part of routine clinical testing
(daily routine samples). A minimum of 500 fresh (where possible)
samples were provided and tested by each center, and speciﬁcity
(including 95% conﬁdence intervals) calculated using statistical
software package SPSS 11.0.
Results for the Elecsys® HIV combi PT are expressed as a sig-
nal to cut-off ratio (s/co) and considered to be negative if the s/co
<0.9 and positive if the s/co ≥1.0. An s/co between 0.9 and <1.0
is considered borderline17; as a safety measure, within this study
borderline resultswere taken to be positive. Each assaywas used inpreted accordingly. Initially reactive samples were conﬁrmed by
Western blot, Elecsys® HIV Ag test, Elecsys® HIV Ag conﬁrmatory
test, or HIV RNA testing and the conﬁrmatory test(s) used by each
center are shown in Table 1.
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Table 1
Centers involved in the study, methods used, and samples tested.
Center Comparison method(s) Conﬁrmation HIV antibody or
antigen assay or HIV RNA NAT
Sample type or source (no. of samples)
The Catholic University of
Korea, Seoul St. Mary’s
Hospital, Seoul, Korea
ADVIA Centaur® HIV Ag/Ab
combo
Elecsys® HIV Ag test
Elecsys® HIV Ag conﬁrmatory
test
HIV RNA NAT
HIV-1 subtyped lysate dilutions (25)
HIV-1 subtyped antibody dilutions (20)
Seroconversion panels NABI 0759, 4009, 25165, and
SeraCare PRB 930 (25)
NIBSC WHO p24 antigen standard material (7)
Routine samples (1039)
Department of Laboratory
Medicine, Korea
University Hospital,
Seoul, Korea
ARCHITECT® HIV Ag/Ab
combo
HIV immunoblot
Elecsys® HIV Ag test
Elecsys® HIV Ag conﬁrmatory
test
HIV-1 subtyped lysate dilutions (25)
HIV-1 subtyped antibody dilutions (20)
Seroconversion panels NABI 0759, 4009, 25165, and
SeraCare PRB 958 (27)
NIBSC WHO p24 antigen standard material (7)
Routine samples, including high-risk patients,
check-up patients, hepatitis B/C, and dialysis patients
(1000)
The First Hospital of China
Medical University,
Clinical Laboratory
Department, Shenyang,
China
ARCHITECT® HIV Ag/Ab
combo
VIRONOSTIKA® HIV
Uni-Form II Plus O
HIV immunoblot
Elecsys® HIV Ag test
Elecsys® HIV Ag conﬁrmatory
test
HIV-1 subtyped lysate dilutions (25)
HIV-1 subtyped antibody dilutions (20)
Seroconversion panels NABI 9003, 4009, 1436, and
SeraCare PRB 930 (22)
Early HIV infections sample; time since infections
9–837 days (39)
NIBSC WHO p24 antigen standard material (7)
Routine samples (703)
West China Hospital,
Sichuan University,
Chengdu, China
Elecsys® HIV combi
Zhuhai Livzon Anti-HIV EIA
HIV immunoblot
Elecsys® HIV Ag test
Elecsys® HIV Ag conﬁrmatory
test
HIV RNA NAT
HIV-1 subtyped lysate dilutions (25)
HIV-1 subtyped antibody dilutions (20)
Known HIV-1 antibody-positive samples (30)
Seroconversion panels NABI 0759, 25165, 1436, 9003,
and SeraCare PRB 930 (35)
Unselected routine samples (543)
Potentially interfering samples, including
end-stage renal disease, autoimmune diseases, HBsAg
positive, anti-HBs positive, icterus, hemolysis, lipemia
(132)
Virology Unit, Institute for
Medical Research, Kuala
Lumpur, Malaysia
Elecsys® HIV combi
Serodia® HIV1/2 Particle
Agglutination
HIV immunoblot
Elecsys® HIV Ag test
Elecsys® HIV Ag conﬁrmatory
test
HIV-1 subtyped lysate dilutions (25)
HIV-1 subtyped antibody dilutions (20)
Known HIV-1 antibody-positive samples (153)
Seroconversion panels NABI 0759, 25165, 1436, 9003,
and SeraCare PRB 930 (35)
Department of Medical
Microbiology, University
Malaya Medical Centre,
Kuala Lumpur, Malaysia
ARCHITECT® HIV Ag/Ab
combo
HIV immunoblot
Elecsys® HIV Ag test
Elecsys® HIV Ag conﬁrmatory
test
PA assay
HIV-1 subtyped lysate dilutions (25)
HIV-1 subtyped antibody dilutions (20)
Seroconversion panels NABI 4009, 25165, 1436, 9003,
and SeraCare PRB 958 (30)
NIBSC WHO p24 antigen standard material (7)
Routine samples; ante-natal care testing, blood donors,
clinical routine (1048)
Ab=antibody; Ag= antigen; HBs=hepatitis B surface; HIV=human immunodeﬁciency virus; NAT=nucleic acid test; NIBSC=National Institute for Biological Standards and
Control; RNA= ribonucleic acid; WHO=World Health Organization.
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3. Results
The Elecsys® HIV combi PT assay was more sensitive at detec-
ing all virus lysate subtypes than the ADVIA Centaur® HIV combo
nd Elecsys® HIV combi assays (Table 2). Sensitivity between the
lecsys® HIV combi PT and ARCHITECT® HIV combo assays was
imilar for subtypes B, C, and F, but the Elecsys® HIV combi PT
ssay detected subtypes A and CRF01 AE one dilution step lower
han the ARCHITECT® assay. The Elecsys® HIV combi PT assay was
ore sensitive at detecting antibodies to all subtypes than the
ajority of comparators, with similar sensitivity to the Elecsys®
IV combi assay (Table 2). Furthermore, two centers tested a total
f 183 samples from the region known to be HIV positive. The
lecsys® HIV combi PT and Elecsys® HIV combi assays correctly
iagnosed 183/183 samples, while the Zhuhai Livzon Anti-HIV EIA
nd Serodia® Particle Agglutination assays correctly diagnosed the
0/30 and 153/153 samples tested, respectively.Results from the seroconversion panel analyses are given in
Table 3. The Elecsys® HIV combi PT assay detected HIV infection
at a similar time to the ARCHITECT® HIV combo assay, but 0.8 days
earlier than the Elecsys® HIV combi, 1.0 days earlier than theADVIA
Centaur® HIV combo, 5.0 days earlier than Zhuhai Livzon Anti-HIV
EIA, 6.0 days earlier than VIRONOSTIKA® HIV Uni-Form II PlusO,
and 6.6 days earlier than the Serodia® Particle Agglutination assay.
In addition, using the 39 samples taken from patients at different
time points between 9 and >800 days after infection, the Elecsys®
HIV combi PT and ARCHITECT® HIV combo assays detected all sam-
ples as positive. However, the VIRONOSTIKA® HIV Uni-Form II Plus
O assay, a third-generation test, reported one sample as borderline
and six false-negative results.The lower detection limit of the fourth-generation assays was
similar andconforms to that for obtainingCEapproval (<2 IU/mL).11
Combining the data generated by the sites for each assay resulted in
an analytical sensitivity of 0.90 IU/mL for the Elecsys® HIV combi PT
224 C.M. Tao et al. / Journal of Clinical Virology 58 (2014) 221–226
Table 2
Assay sensitivity for detecting HIV-1 subtype antigen or antibody. Dilutions of viral lysates and antibody-positive samples were prepared for various HIV-1 subtypes and
tested for p24 antigen or HIV-1-speciﬁc antibody.
HIV subtype Elecsys® HIV
combi PT
Elecsys® HIV
combi
ADVIA Centaur®
HIV combo
ARCHITECT® HIV
combo
VIRONOSTIKA®
HIV Uni-Form II
Plus O
Zhuhai Livzon
Anti-HIV EIA
Serodia® Particle
Agglutination
HIV antigen
A 1:64,000 1:16,000 1:32,000 1:128,000 N/A N/A N/A
B 1:37,280 1:9320 1:18,640 1:37,280 N/A N/A N/A
C 1:53,440 1:6680 1:26,720 1:53,440 N/A N/A N/A
CRF01 AE 1:31,968 1:7992 1:3996 1:63,936 N/A N/A N/A
F 1:15,936 1:1992 1:7968 1:15,936 N/A N/A N/A
HIV antibody
A 1:170,000 1:170,000 1:17,000 1:17,000 1:17,000 1:17,000 1:17,000
B 1:15,000 1:15,000 1:1500 1:1500 1:1500 1:1500 1:1500
C 1:100,000 1:100,000 1:10,000 1:10,000 1:10,000 1:1000 1:100,000
D 1:142,500 1:28,500 1:28,500 1:2850 1:28,500 1:2850 1:285
CRF01 AE 1:50,000 1:50,000 1:5000 1:500 1:5000 1:500 1:500
HIV=human immunodeﬁciency virus; N/A=not applicable for third-generation assays.
Table 3
Seroconversion sensitivity data using the Paul Ehrlich Institute calculation method.
Seroconversion panel Elecsys® HIV
combi PT
Elecsys® HIV
combi
ADVIA Centaur®
HIV combo
ARCHITECT® HIV
combo
VIRONOSTIKA®
HIV Uni-Form II
Plus O
Zhuhai Livzon
Anti-HIV EIA
Serodia® Particle
Agglutination
PRB 930 0 4 4 0 8 8 8
PRB 958 8 NA NA 8 NA NA NA
NABI 0759 0 0 0 0 NA 4 8
NABI 1436 0 0 NA 0 9 9 9
NABI 4009 0 NA 0 0 3 NA NA
NABI 9003 6 6 NA 6 10 6 10
NABI 25165 0 0 0 0 NA 4 4
Mean number of days to a positive result across:a
7 panels 2.0 – – 2.0 – – –
5 panels 1.2 2.0 – – – 6.2 7.8
4 panels 0.0 – 1.0 – – – –
4 panels 1.5 – – – 7.5 – –
Day of bleeding with ﬁrst positive results (last negative sample plus 1 day) compared with PCR or p24 antigen data provided by the panel suppliers (SeraCare and North
A was c
P
a
f
f
h
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t
5
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T
T
H
pmerican Biologicals). The ﬁrst positive bleed with the PCR or p24 antigen assay
CR=polymerase chain reaction.
a Values were calculated separately for each combination of panels tested.
ssay, 0.74 IU/mL for the ARCHITECT® HIV combo, and 1.70 IU/mL
or the ADVIA Centaur® HIV combo assay.
The speciﬁcity of each assay was calculated by combining data
rom the different sites. The Elecsys® combi PT assay showed very
igh speciﬁcity (99.86%) that was slightly better than that of the
RCHITECT® HIV combo (99.78%), ADVIA Centaur® HIV combo
99.52%), and Elecsys® HIV combi (99.85%) assays, but lower than
he two third-generation assays tested (see Table 4).. Discussion
This is the ﬁrstmulticenter study in Asia to validate the Elecsys®
IV combi PT assay for HIV screening. By testing a large sample
able 4
he overall speciﬁcity of each assay calculated by combining the data obtained from testin
Elecsys® HIV
combi PT
Elecsys® HIV
combi
ADVIA C
HIV com
Total number 4465 675 1039
IR (≥1 s/co) 51 1 5
Conﬁrmed positive 45 0 0
Number of false positivesa 6 1 5
Speciﬁcity (IR, ≥1 s/co) 99.86% 99.85% 99.52%
95% Conﬁdence limit (IR, ≥1 s/co) 99.71–99.95 99.18–100.00 98.88–9
IV=human immunodeﬁciency virus; IR = initially reactive; s/co = signal/cut-off.
a Identiﬁed as negative by HIV-1 Western blot, anti-HIV particle agglutination or HIV
ositive. The speciﬁcity of the Serodia® Particle Agglutination test was not included becaonsidered to be day 0. HIV=human immunodeﬁciency virus; NA=not available;
number, robust data have been generated demonstrating that the
Elecsys® HIV combi PT assay: had good subtype inclusivitywith the
ability to detect all HIV-1 subgroups routinely found in Asia; reli-
ably differentiated between HIV-positive and -negative samples;
and detected infection early within the disease course. In addition,
the performance of the assay was comparable or superior to the
other assays tested.
HIV is a highly variable virus and maintains this diversity
through ‘error-prone’ rapid replicationandrecombinationbetween
different HIV subtypes within the same person.24 While hetero-
geneity allows the virus to effectively overcome both the host’s
immune system and therapeutic interventions, it varies geograph-
ically and creates a challenge for screening.15,25,26 Screening tests
g routine samples and samples with potentially interfering substances at each site.
entaur®
bo
ARCHITECT® HIV
combo
VIRONOSTIKA®
HIV Uni-Form
II Plus O
Zhuhai Livzon
Anti-HIV EIA
2751 703 675
50 2 0
44 2 0
6 0 0
99.78% 100.00% 100.00%
9.84 99.52–99.92 99.48–100.00 99.45–100.00
antigen assay testing. In these analyses, borderline results were considered to be
use of pre-selection bias.
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hould ideally detect infection regardless of genotype and rec-
gnize infection with the subtypes and recombinants commonly
ound in the region of use.15 The HIV-1 subtypes frequently found
n Asia are B, C, and CRF01 AE, a recombinant form described
n Thailand, Cambodia, Vietnam, Malaysia, China, Taiwan, Korea,
nd Japan.24–26 The Elecsys® HIV combi PT assay detected known-
ositive samples as well as HIV-1 antigen or antibody regardless
f subtype and, in general, with a similar or greater sensi-
ivity than the comparator assays. Our ﬁndings support those
ublished previously16,27 and conﬁrm the high antibody sen-
itivity of the assay; combined with good antigen sensitivity
his afﬁrms use of the Elecsys® HIV combi PT assay to reduce
he diagnostic window period in clinical practice.27 Further-
ore, previous studies found that the Elecsys® assay successfully
etected HIV-2 antigen and antibodies with greater sensitivity
han other assays tested.15,16 Hence the available data show that
he Elecsys® HIV combi PT assay detects infection with all sub-
ypes and variants, including those frequently encountered in
sia.
The speciﬁcity of the Elecsys® HIV combi PT assay was good
99.86%) and better than that determined previously in European
99.81%; unselected samples) and Korean (99.5%) samples.16,27 In
ddition, results for the comparator assays are in agreement with
hose reported previously, such as 99.8% for the Elecsys® HIV combi
ssay,12 >99.5% for the ARCHITECT® HIV combo assay,13,16,27–30
nd 99.3%/99.74% for the ADVIA Centaur® HIV combo assay.16,31
he speciﬁcity of the Serodia® Particle Agglutination assay was
eported previously as >99.97%,14,32 and that of the VIRONOSTIKA®
IV Uni-Form II Plus O assay ranged from 97.9 to 100.0%.14,33–35
hese ﬁndings support the validity of the data, afﬁrm the speciﬁcity
f the Elecsys® HIV combi PT assay using real-world samples from
he Asian population, and demonstrate that the assay is suitable for
se in routine HIV screening in Asia.
While the speciﬁcity of the third-generation assays –
IRONOSTIKA® HIV Uni-Form II Plus O and Zhuhai Livzon Anti-
IV EIA assays – was 100% in this study, these assays lacked
ensitivity in the early stages of infection meaning that positive
amples can be missed. This was highlighted by the investiga-
ion of samples taken 9 to >800 days after infection, and the
eroconversion panel data. The Elecsys® HIV combi PT assay
etected seroconversion 5.0, 6.0, and 6.6 days earlier than the
huhai LivzonAnti-HIV EIA, VIRONOSTIKA® HIVUni-Form II PlusO,
nd Serodia® Particle Agglutination assays, respectively (Table 3).
hese results are consistent with previous studies demonstrating
hat fourth-generation immunoassays detect infection sooner than
hird-generationassays12,13,31,36,37 and that theElecsys® HIVcombi
T assay detects seroconversion at a similar time or sooner than
ther assays.16,27 Early detection of HIV infection is vital as it can
educe unknown spread of the virus and allows early initiation of
reatment which can, in turn, increase life expectancy.38,39 There-
ore, diagnostic use of a fourth-generation assay is indispensable in
his context. While third-generation tests are still frequently used
n some regions,40,41 fourth-generation screening assays are now
ecommended for HIV testing in European sexually transmitted
nfection clinics and by the WHO.42,43
The performance of the Elecsys® HIV combi PT assay in this
tudy was similar to that published previously,15,16,27 although the
nalytical sensitivity was lower (0.90 IU/mL) than in other stud-
es (1.095 IU/mL, 1.05 IU/mL, and 1.13 IU/mL, respectively).15,16,27
his, and the superior or comparable performance to that of the
lecsys® HIV combi assay, provides reassuring evidence on the per-
ormance of the improved assay and demonstrates that it not only
eets European requirements, but is also appropriate for use in
sia. Hence, the assay offers automated high-throughput screening
ith the ability to detect early infection in a variety of geographical
ettings.
1irology 58 (2014) 221–226 225
This study validated the Elecsys® HIV combi PT assay for
screening and reliable early detection of HIV infection in Asia. The
assaywas rigorously tested inover4000samplesanddemonstrated
excellent sensitivity and speciﬁcity and a diagnostic window that
was shorter or similar to that of the comparator assays. Therefore,
use of the Elecsys® HIV combi PT assay in Asia may improve the
number of AHI cases identiﬁed compared with other fourth- and
third-generation assays currently used in this region.
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